Platelet serotonin modulates immune functions

Hamostaseologie

Volumn 36, Issue 1, 2016, Pages 11-16

  Mauler, M ^a   Bode, C ^a   Duerschmied, D ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Inflammatory mediators; Leukocyte activation; Leukocyte function; Platelet immunology

Indexed keywords

FLUOXETINE; SELECTIN; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRIPTAN DERIVATIVE;

ALLERGIC ASTHMA; ASTHMA; AUTOIMMUNE DISEASE; BRAIN ISCHEMIA; ENDOTHELIUM CELL; EXTRACELLULAR TRAP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE; LIVER ISCHEMIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEOPLASM; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SEROTONIN BLOOD LEVEL; SURVIVAL; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTE ACTIVATION; TISSUE REGENERATION; VIRUS HEPATITIS; ANIMAL; BIOLOGICAL MODEL; IMMUNOLOGY; INNATE IMMUNITY; PATHOLOGY;

ANIMALS; BLOOD PLATELETS; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; INFLAMMATION; MODELS, CARDIOVASCULAR; MODELS, IMMUNOLOGICAL; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; SEROTONIN;

EID: 84964794137     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-14-11-0073     Document Type: Review

References (72)

1. Rapport MM, Green AA, Page IH. Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem 1948; 176: 1243-1251.
2. Rapport MM, Green AA, Page IH. Serum vasoconstrictor, serotonin; chemical inactivation. J Biol Chem 1948; 176: 1237-1241.
3. Berger J, Hauber J, Hauber R et al. Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. Gene 1988; 66: 1-10.
4. Veenstra-VanderWeele J, Anderson GM, Cook EH Jr. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol 2000; 410: 165-181.
5. Walther DJ, Peter JU, Winter S et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 2003; 115: 851-862.
6. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Ann Rev Med 2009; 60: 355-366.
7. Walther DJ, Peter JU, Bashammakh S et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299: 76.
8. Mossner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 1998; 12: 249-271.
9. Yadav VK, Ryu JH, Suda N et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008; 135: 825-837.
10. McNicol A, Israels SJ. Platelet dense granules: structure, function and implications for haemostasis. Thromb Res 1999; 95: 1-18.
11. Blakely RD, Ramamoorthy S, Schroeter S et al. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol Psychiatry 1998; 44: 169-178.
12. Ramamoorthy S, Blakely RD. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 1999; 285: 763-766.
13. Beckman ML, Quick MW. Substrates and temperature differentiate ion flux from serotonin flux in a serotonin transporter. Neuropharmacology 2001; 40: 526-535.
14. Carneiro AM, Blakely RD. Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. J Biol Chem 2006; 281: 24769-24780.
15. Brenner B, Harney JT, Ahmed BA et al. Plasma serotonin levels and the platelet serotonin transporter. J Neurochem 2007; 102: 206-215.
16. Ahmed BA, Jeffus BC, Bukhari SI et al. Serotonin transamidates Rab4 and facilitates its binding to the C terminus of serotonin transporter. J Biol Chem 2008; 283: 9388-9398.
17. Hoyer D, Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology. 1997; 36: 419-428.
18. Martin C, Duclos M, Mormede P et al. Hippocampal and striatal [3H]5-HT reuptake under acute stressors in two rat strains differing for their emotivity. Neuroscience Lett 2000; 288: 246-248.
19. Gordon J, Barnes NM. Lymphocytes transport serotonin and dopamine: agony or ecstasy? Trends Immunol 2003; 24: 438-443.
20. Meredith EJ, Holder MJ, Chamba A et al. The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics. FASEB J 2005; 19: 1187-1189.
21. Cloez-Tayarani I, Changeux JP. Nicotine and serotonin in immune regulation and inflammatory processes: a perspective. J Leukoc Biol 2007; 81: 599-606.
22. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414.
23. De Jong WH, Wilkens MH, de Vries EG, Kema IP. Automated mass spectrometric analysis of urinary and plasma serotonin. Anal Bioanal Chem 2010; 396: 2609-2616.
24. Iken K, Chheng S, Fargin A et al. Serotonin upregulates mitogen-stimulated B lymphocyte proliferation through 5-HT1A receptors. Cell Immunol 1995; 163: 1-9.
25. Ito T, Ikeda U, Shimpo M et al. Serotonin increases interleukin-6 synthesis in human vascular smooth muscle cells. Circulation 2000; 102: 2522-2527.
26. Cloutier N, Pare A, Farndale RW et al. Platelets can enhance vascular permeability. Blood 2012; 120: 1334-1343.
27. Duerschmied D, Suidan GL, Demers M et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 2013; 121: 1008-1015.
28. Durk T, Duerschmied D, Muller T et al. Production of serotonin by tryptophan hydroxylase 1 and release via platelets contribute to allergic airway inflammation. Am J Respir Crit Care Med 2013; 187: 476-485.
29. Durk T, Panther E, Muller T et al. 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes. Int Immunol 2005; 17: 599-606.
30. Yu B, Becnel J, Zerfaoui M et al. Serotonin 5-hydroxytryptamine( 2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther 2008; 327: 316-323.
31. Muller T, Durk T, Blumenthal B et al. 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One 2009; 4: e6453.
32. Gershon RK. A disquisition on suppressor T cells. Transplant Rev 1975; 26: 170-185.
33. Askenase PW, Metzler CM, Gershon RK. Localization of leucocytes in sites of delayed-type hypersensitivity and in lymph nodes: dependence on vasoactive amines. Immunology 1982; 47: 239-246.
34. Fuchs BA, Campbell KS, Munson AE. Norepinephrine and serotonin content of the murine spleen: its relationship to lymphocyte beta-adrenergic receptor density and the humoral immune response in vivo and in vitro. Cell Immunol 1988; 117: 339-351.
35. Ameisen JC, Meade R, Askenase PW. A new interpretation of the involvement of serotonin in delayed- type hypersensitivity. Serotonin-2 receptor antagonists inhibit contact sensitivity by an effect on T cells. J Immunol 1989; 142: 3171-3179.
36. Askenase PW, Herzog WR, Millet I et al. Serotonin initiation of delayed-type hypersensitivity: mediation by a primitive Thy-1+ antigen-specific clone or by specific monoclonal IgE antibody. Skin Pharmacol 1991; 4 (Suppl 1): 25-42.
37. Gobin V, Van Steendam K, Denys D, Deforce D. Selective serotonin reuptake inhibitors as a novel class of immunosuppressants. Int Immunopharmacol 2014; 20: 148-156.
38. Latendresse G, Ruiz RJ, Wong B. Psychological distress and SSRI use predict variation in inflammatory cytokines during pregnancy. Open J Obstet Gynecol 2013; 3: 184-191.
39. Geba GP, Ptak W, Anderson GM et al. Delayedtype hypersensitivity in mast cell-deficient mice: dependence on platelets for expression of contact sensitivity. J Immunol 1996; 157: 557-565.
40. Segal AW. How neutrophils kill microbes. Ann Rev Immunol 2005; 23: 197-223.
41. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006; 6: 173-182.
42. Rubin-Bejerano I, Abeijon C, Magnelli P et al. Phagocytosis by human neutrophils is stimulated by a unique fungal cell wall component. Cell Host Microbe 2007; 2: 55-67.
43. Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007; 5: 577-582.
44. Fuchs TA, Brill A, Duerschmied D et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-15885.
45. Herr N, Mauler M, Witsch T et al. Acute fluoxetine treatment induces slow rolling of leukocytes on endothelium in mice. PLoS One 2014; 9: e88316.
46. Durk T, Duerschmied D, Muller T et al. Production of serotonin by tryptophan hydroxylase 1 and release via platelets contribute to allergic airway inflammation. Am J Respir Crit Care Med 2013; 187: 476-485.
47. Eddahibi S, Humbert M, Fadel E et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-1150.
48. Lederer DJ, Horn EM, Rosenzweig EB et al. Plasma serotonin levels are normal in pulmonary arterial hypertension. Pulm Pharmacol Ther 2008; 21: 112-114.
49. Liu Y, Gao XM, Fang L et al. Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction. Arterioscler Thromb Vasc Biol 2011; 31: 834-841.
50. Ho-Tin-Noe B, Goerge T, Cifuni SM et al. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res 2008; 68: 6851-6858.
51. Skolnik G, Ericson LE, Bagge U. The effect of thrombocytopenia and antiserotonin treatment on the lodgement of circulating tumor cells. A vital fluorescence microscopic, electron microscopic and isotope study in the rat. J Cancer Res Clin Oncol 1983; 105: 30-37.
52. Soll C, Jang JH, Riener MO et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology 2010; 51: 1244-1254.
53. Lee MS, Cheng FC, Yeh HZ et al. Determination of plasma serotonin and 5-hydroxyindoleacetic acid in healthy subjects and cancer patients. Clin Chem 2000; 46: 422-423.
54. Dowling P, Hughes DJ, Larkin AM et al. Elevated levels of 14-3-3 proteins, serotonin, gamma enolase and pyruvate kinase identified in clinical samples from patients diagnosed with colorectal cancer. Clin Chim Acta 2014; 441C: 133-141.
55. Lang PA, Contaldo C, Georgiev P et al. Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med 2008; 14: 756-761.
56. Iannacone M, Sitia G, Guidotti LG. On the role of platelets in the pathogenesis of viral hepatitis. J Hepatol 2009; 51: 599-600.
57. Spengler U. Hepatic microcirculation: a critical but neglected factor for the outcome of viral hepatitis. J Hepatol 2009; 50: 631-633.
58. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135.
59. Shimizu Y, Minatoguchi S, Hashimoto K et al. The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts. J Am Coll Cardiol 2002; 40: 1347-1355.
60. Simpson PJ, Schelm JA, Jakubowski JA, Smallwood JK. The role of serotonin (5HT2) receptor block-ade in myocardial reperfusion injury: effects of LY53857 in a canine model of myocardial infarction. J Pharmacol Exp Ther 1991; 258: 979-985.
61. Nebigil CG, Etienne N, Messaddeq N, Maroteaux L. Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT2B receptor signaling. FASEB J 2003; 17: 1373-1375.
62. Lesurtel M, Graf R, Aleil B et al. Platelet-derived serotonin mediates liver regeneration. Science 2006; 312: 104-107.
63. Nocito A, Georgiev P, Dahm F et al. Platelets and platelet-derived serotonin promote tissue repair after normothermic hepatic ischemia in mice. Hepatology 2007; 45: 369-376.
64. Puente J, Jaque M, Carrasco C et al. Triptan drugs, natural killer cell cytotoxicity, and neutrophils pro-matrix metalloproteinase-9 secretion. Headache 2008; 48: 1482-1489.
65. Hellstrand K, Hermodsson S. Role of serotonin in the regulation of human natural killer cell cytotoxicity. J Immunol 1987; 139: 869-875.
66. Mostert JP, Admiraal-Behloul F, Hoogduin JM et al. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebocontrolled, exploratory study. J Neurol Neurosurg Psychiatry 2008; 79: 1027-1031.
67. Bird H, Broggini M. Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double blind, parallel group study. J Rheumatol 2000; 27: 2791-2797.
68. Lechin F, van der Dijs B, Orozco B et al. Increased levels of free serotonin in plasma of symptomatic asthmatic patients. Ann Allergy Asthma Immunol 1996; 77: 245-253.
69. Kereveur A, Callebert J, Humbert M et al. High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol 2000; 20: 2233-2239.
70. Hara K, Hirowatari Y, Yoshika M et al. The ratio of plasma to whole-blood serotonin may be a novel marker of atherosclerotic cardiovascular disease. J Lab Clin Med 2004; 144: 31-37.
71. Figueras J, Domingo E, Cortadellas J et al. Comparison of plasma serotonin levels in patients with variant angina pectoris versus healed myocardial infarction. The Am J Cardiol 2005; 96: 204-207.
72. Sundar IK, Yao H, Huang Y et al. Serotonin and corticosterone rhythms in mice exposed to cigarette smoke and in patients with COPD: implication for COPD-associated neuropathogenesis. PLoS One 2014; 9: e87999.